在线观看一区二区视频,日本新japanese乱熟,日韩av影院在线观看

GSK Full Year 2025 Financial Report GSK GSK reported ￡32.7B revenue in 2025, up 4% YoY, driven by specialty medicines and vaccines. Core profit rose 7%, with strong R&D pipeline and steady global growth supporting 2026 outlook.
Global Biopharma Layoffs February 2026 Layoffs Global Biopharma companies including GSK, IO Biotech, and Bitterroot Bio announce workforce reductions in February 2026 as part of cost-saving and strategic realignments, impacting research, technology, and leadership roles across their operations.
Global Biopharma Layoffs October 2025 Layoffs This article tracks recent biotech and pharma layoffs, including major workforce cuts at Novo Nordisk, Takeda, GSK, Pharming, and others, as companies restructure operations, streamline pipelines, and refocus resources amid shifting market conditions.
GSK 2025 H1 Performance GSK GSK reports strong H1 2025 results with ￡15.5B revenue. Oncology grows 47%, HIV remains robust, and vaccines stay steady. Company targets ￡40B+ annual sales by 2031.
Global Biopharma Layoffs July 2025 Layoffs Biopharmaceutical industry sees major July layoffs, with companies like Sarepta, GSK, Century, and Sage Therapeutics cutting jobs amid restructurings, trial setbacks, and M&A activity.
GSK and Bharat Biotech to Cut Malaria Vaccine Cost GSK GSK and Bharat Biotech plan to reduce the cost of Mosquirix, the world’s first WHO-approved malaria vaccine, to under $5 per dose by 2028, aiming to expand global access and support Gavi’s child immunization goals across Africa.
GSK Strengthens Blenrep's Case with New Data GSK GSK’s Blenrep demonstrates significant progression-free survival improvements in multiple myeloma trials DREAMM-8 and DREAMM-7, strengthening its case for a U.S. market return with FDA decision expected by July 2025.
GSK's Blenrep Gains EU Backing in New Combo Use GSK GSK’s Blenrep gains CHMP recommendation for combination use in multiple myeloma, marking a comeback after U.S. withdrawal. Novartis withdraws Lutathera EU expansion. Other CHMP approvals and rejections detailed.
GSK Gains Ground in COPD Market with Nucala GSK GSK’s Nucala has received FDA approval as an add-on treatment for eosinophilic COPD, positioning it against Dupixent. Backed by strong trial results, GSK targets $669M in peak annual sales for the new indication.
The Global Vaccine Market: How Pfizer, Merck, GSK & Sanofi Maintain Their Dominance Market Trend As the pandemic subsides, the industry is returning to pre-pandemic dynamics, with Pfizer strengthening its pneumonia vaccine leadership, Merck betting on HPV and RSV, GSK focusing on meningitis, and Sanofi expanding its RSV monoclonal antibody business.

<Pre12 Next >

Articles Archives

Hot Articles

All Categories

Agri & Industry Cosmetic Laboratory Pharmaceutical Food

永久免费毛片_亚洲成人看片_亚洲春色另类_亚洲综合免费视频_最新高清无码专区_午夜影院a